证券代码：300404 证券简称：博济医药 公告编号：2025-060 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次归属限制性股票的激励对象合计 29 名，归属限制性股票数量合计 506,400 股，占目前公司总股本的 0.1315%。 2、本次归属股份的上市流通日：2025 年 7 月 30 日。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 了第五届董事会第十三次会议和第五届监事会第十二次会议，审议通过了《关于 公司 2023 年限制性股票激励计划首次授予部分第二个解除限售期及预留授予部 分第一个解除限售期解除限售条件成就、首次授予部分第二个归属期归属条件成 就的议案》，董事会认为公司 2023 年限制性股票激励计划（以下简称"本激励 计划"）首次授予部分第二个归属期归属条件已成就。近日，公司办理了第二个 归属期归属股份的登记工作。现将有关情况公告如下： 一、公司 2023 年限制性股票激励计划概述及已履行的相关程序 博济医药科技股份有限公司 关于公司 2023 年限制性股票激励计划 首次授予部 ...

Market Overview - As of July 17, the Shanghai Composite Index closed at 3516.83 points, up 13.05 points, with a gain of 0.37% [1] - The Shenzhen Component Index closed at 10873.62 points, up 152.81 points, with a gain of 1.43% [1] - The ChiNext Index closed at 2269.33 points, up 39.13 points, with a gain of 1.75% [1] Stock Performance - A total of 83 A-shares had a turnover rate exceeding 20% on this day, with Xinning Electric achieving a turnover rate of over 50% [1] - The top stocks by turnover rate included: - Xinning Electric (301388) with a closing price of 38.30 yuan and a turnover rate of 52.50%, up 0.31% [1] - Dayilong (002209) with a turnover rate of 49.98%, closing at 17.09 yuan, down 7.82% [1] - Beifang Changlong (301357) with a turnover rate of 48.34%, closing at 85.47 yuan, up 5.88% [1] - Mankun Technology (301132) with a turnover rate of 45.59%, closing at 39.88 yuan, up 20.01% [1] Notable Stocks - Other notable stocks with high turnover rates included: - Tongguan Copper Foil (301217) with a turnover rate of 40.44%, closing at 20.86 yuan, up 13.37% [1] - Yida Technology (301176) with a turnover rate of 36.95%, closing at 35.16 yuan, up 6.19% [1] - Nanjing Julong (300644) with a turnover rate of 29.86%, closing at 33.59 yuan, up 20.01% [1] Additional Stock Insights - Stocks with significant price movements included: - Huanbo Technology (002229) with a turnover rate of 34.18%, closing at 20.56 yuan, up 10.01% [1] - ST Lifan (300280) with a turnover rate of 24.36%, closing at 3.17 yuan, down 7.85% [2] - Shanghai Steel Union (300226) with a turnover rate of 22.51%, closing at 30.37 yuan, up 2.74% [3]

Core Viewpoint - The brain engineering sector experienced a rise of 1.48% on July 17, with a total capital outflow of 385.08 million [1] Group 1: Stock Performance - A total of 27 stocks in the sector increased in value, while 5 stocks declined [1] - The top-performing stocks included: - Seli Medical: +10.01% - Boji Pharmaceutical: +9.5% - Innovation Medical: +3.23% - Pulite: +3.03% - Beilu Pharmaceutical: +2.6% [1] Group 2: Capital Flow - Major stocks with significant capital inflow included: - Innovation Medical: +16.07 million, accounting for 2.21% - Seli Medical: +199 million, accounting for 15.64% [1] - Stocks with capital outflow included: - Boji Pharmaceutical: -2.46 million, accounting for -2.82% - Beilu Pharmaceutical: -1.41 million, accounting for -3.62% [1] Group 3: Declining Stocks - The stocks that saw the largest declines included: - ST Huatuo: -4.77% - Botuo Bio: -1.59% - Hanwei Technology: -1.49% [1]

Group 1 - The innovative drug sector showed strong performance in the morning session, with Han Commercial Group (600774) hitting the daily limit up [1] - Weikang Pharmaceutical (300878) and Chengdu Xian Dao both surged over 15% [1] - Other companies such as Saily Medical (603716), Nanxin Pharmaceutical, and Boji Pharmaceutical (300404) also experienced gains [1] Group 2 - Dark pool funds are flowing into these stocks, indicating increased investor interest [1]

Group 1 - The A-share innovative drug sector continues to show strong performance, with Weikang Pharmaceutical hitting a 20% daily limit increase [1] - Seer Medical also reached its limit, while companies such as Nanjing New Pharmaceutical, Lianhuan Pharmaceutical, Anglikang, and Boji Medical experienced upward trends [1]

Group 1 - The Alzheimer's concept sector increased by 2.28%, ranking fifth among concept sectors, with 27 stocks rising, including Wanbangde, Lisheng Pharmaceutical, and Zhejiang Zhenyuan reaching the daily limit [1] - Notable gainers in the sector included Jihua Group, Xinhua Pharmaceutical, and Boji Pharmaceutical, which rose by 5.85%, 4.98%, and 4.93% respectively [1] - The sector experienced a net inflow of 498 million yuan from main funds, with 21 stocks receiving net inflows, and six stocks seeing inflows exceeding 50 million yuan [2] Group 2 - The top stock in terms of net inflow was Huahai Pharmaceutical, with a net inflow of 87.51 million yuan, followed by Boji Pharmaceutical, Jihua Group, and Haizheng Pharmaceutical with inflows of 55.18 million yuan, 54.13 million yuan, and 53.91 million yuan respectively [2][3] - Zhejiang Zhenyuan and Boji Pharmaceutical had the highest net inflow ratios at 29.25% and 16.16% respectively [3] - The overall performance of the Alzheimer's concept sector was supported by significant trading volumes, with stocks like Lisheng Pharmaceutical and Wanbangde showing substantial price increases of 10% [4]

博济医药科技股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 二、 监事会会议审议情况 经审核，监事会一致认为：公司本次调整股票期权激励计划行权价格事项符 合公司《2022 年股票期权激励计划（草案）》《2022 年股票期权激励计划实施考 核管理办法》等有关规定，不存在损害公司及全体股东利益的情形。因此，公司 监事会同意本次调整股票期权激励计划行权价格事项。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 价格的议案》 证券代码：300404 证券简称：博济医药 公告编号：2025-057 记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届监事会第十四次会 议于 2025 年 7 月 15 日在公司会议室召开，会议采取现场投票方式对议案进行表 决。本次会议通知于 2025 年 7 月 11 日以专人送达、电子邮件、电话、微信等方 式发出。会议应到监事 3 人，实到 3 人。会议由监事会主席刘菁纯女士主持。本 次监事会的召集、召开符合《公司法》《公司章程》及相关法规的规定。 表决结果：同意 3 票；反对 0 票；弃权 ...

Core Viewpoint - The company has approved adjustments to the stock option incentive plan's exercise price following the completion of the 2024 annual equity distribution, ensuring compliance with relevant regulations and maintaining shareholder interests [1][9][10] Summary by Sections Company Incentive Plan Overview and Procedures - The company held meetings to review and approve various proposals related to the 2022 stock option incentive plan, including the adjustment of the exercise price and the verification of the list of incentive recipients [1][2][3] Independent Opinions and Verification - Independent directors provided opinions on the incentive plan's benefits for the company's sustainable development and confirmed no harm to the interests of the company and shareholders [2][10] Stock Option Grant and Adjustments - The company granted a total of 2,697,000 stock options to 86 eligible recipients on April 12, 2022, with subsequent adjustments due to resignations and voluntary waivers, resulting in 84 recipients ultimately receiving the options [2][3] - The total number of stock options granted was adjusted multiple times due to various factors, including resignations and the completion of profit distribution plans [3][4][5][6] Exercise Price Adjustments - The exercise price of the stock options was adjusted from 8.75 CNY to 8.74 CNY, and further adjustments were made to 8.73 CNY and then to 8.72 CNY, reflecting the company's annual profit distribution [4][9][10] Impact of Adjustments - The adjustments to the stock option exercise price are not expected to have a significant impact on the company's financial status or operational results, nor will they affect the diligence of the management team [9][10] Legal Opinions and Compliance - Legal opinions confirmed that the adjustments to the stock option exercise price comply with relevant regulations and have received the necessary approvals [10]

证券代码：300404 证券简称：博济医药 公告编号：2025-059 博济医药科技股份有限公司 关于作废部分限制性股票并调整限制性股票激励计划 归属价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第五届董事会第十五次会议和第五届监事会第十四次会议，审议通过了《关于作 废部分限制性股票并调整限制性股票激励计划归属价格的议案》，根据公司《2 023 年限制性股票激励计划（草案）》《2024 年限制性股票激励计划（草案）》 等有关规定，鉴于公司部分激励对象因个人原因离职导致其不再具备激励资格， 同意公司作废其已授予但尚未归属的 2023 年限制性股票 40,800 股、2024 年限制 性股票 60,000 股。同时，又因公司完成了 2024 年年度权益分派，向全体股东每 10 股派发现金股利 0.12 元，同意公司 2023 年限制性股票激励计划归属价格由 8. 73 元/股调整为 8.72 元/股，2024 年限制性股票激励计划归属价格由 6.61 元/股调 整为 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-058 博济医药科技股份有限公司 关于调整股票期权激励计划行权价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 7 月 15 日召开 第五届董事会第十五次会议和第五届监事会第十四次会议，审议通过了《关于调 整股票期权激励计划行权价格的议案》，鉴于公司完成了 2024 年年度权益分派， 根据公司《2022 年股票期权激励计划（草案）》《2022 年股票期权激励计划实 施考核管理办法》等有关规定，同意公司 2022 年股票期权激励计划行权价格由 8.73 元/股调整为 8.72 元/股。现将有关情况公告如下： 1、 2022 年 3 月 23 日，公司第四届董事会第十八次会议审议通过了《关于 公司<2022 年股票期权激励计划（草案）>及其摘要的议案》《关于公司<2022 年 股票期权激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会办 理 2022 年股权激励相关事宜的议案》等议案。同日，公司第四届监事会第十六 次会 ...